Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Business Wire•13/08/2026•16:01 ET
0
Whiz Insights
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
- NDA Submission for Seralutinib in PAH On Track for September 2026 Following Receipt of Pre-NDA Type B Meeting Minutes -
Get started
Create a free account to read the full story.